Effects of antirheumatic treatments on the prostaglandin E2 biosynthetic pathway

Arthritis and Rheumatism

Volumn 52, Issue 11, 2005, Pages 3439-3447

  Korotkova, Marina ^a   Westman, Marie ^a   Gheorghe, Karina R ^b   Af Klint, Erik ^a   Trollmo, Christina ^a   Ulfgren, Ann Kristin ^a   Klareskog, Lars ^a   Jakobsson, Per Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; ANTIRHEUMATIC AGENT; BLOCKING AGENT; CD163 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 ANTIBODY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 ANTIBODY; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; LIPOPOLYSACCHARIDE; MICROSOMAL PROSTAGLANDIN E SYNTHASE 1; MICROSOMAL PROSTAGLANDIN E SYNTHASE 1 ANTIBODY; MICROSOME ENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR BLOCKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRITIS; ARTICLE; CELL COUNT; CLINICAL ARTICLE; DOUBLE IMMUNOFLUORESCENCE; DRUG EFFECT; ENZYME IMMUNOASSAY; ENZYME LOCALIZATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; JOINT BIOPSY; MACROPHAGE; MALE; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIUM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRA-ARTICULAR; INTRAMOLECULAR OXIDOREDUCTASES; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SYNOVIAL FLUID; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27744507122     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21390     Document Type: Article

References (46)

1. Portanova JP, Zhang Y, Anderson GD, Hauser SD, Masferrer JL, Seibert K, et al. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 1996;184:883-91.
2. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995;372:83-7.
3. Robinson DR, McGuire MB, Levine L. Prostaglandins in the rheumatic diseases. Ann N Y Acad Sci 1975;256:318-29.
4. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 1999;96:7220-5.
5. Thoren S, Weinander R, Saha S, Jegerschold C, Pettersson PL, Samuelsson B, et al. Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J Biol Chem 2003;278:22199-209.
6. Murakami M, Nakashima K. Kamei D, Masuda S, Ishikawa Y, Ishii T, et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 2003;278:37937-47.
7. Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000;275:32775-82.
8. Thoren S, Jakobsson PJ. Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells: inhibition by NS-398 and leukotriene C4. Eur J Biochem 2000;267:6428-34.
9. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000;275:32783-92.
10. Stichtenoth DO, Thoren S, Bian H, Peters-Golden M, Jakobsson PJ, Crofford LJ. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid-synovial cells. J Immunol 2001;167:469-74.
11. Dieter P, Scheibe R, Jakobsson PJ, Watanabe K, Kolada A, Kamionka S. Functional coupling of cyclooxygenase 1 and 2 to discrete prostanoid synthases in liver macrophages. Biochem Biophys Res Commun 2000;276:488-92.
12. Claveau D, Sirinyan M, Guay J, Gordon R, Chan CC, Bureau Y, et al. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J Immunol 2003;170:4738-44.
13. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 2003;100:9044-9.
14. Kamei D, Yamakawa K, Takegoshi Y, Mikami-Nakanishi M, Nakatani Y, Oh-Ishi S, et al. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1. J Biol Chem 2004;279:33684-95.
15. Westman M, Korotkova M, af Klint E, Stark A, Audoly LP, Klareskog L, et al. Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium. Arthritis Rheum 2004;50:1774-80.
16. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
17. Crofford LJ. Clinical experience with specific COX-2 inhibitors in arthritis [review], Curr Pharm Des 2000;6:1725-36.
18. Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer? [review]. Drugs 2003;63:33-45.
19. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.
20. Lundberg IE, Grundtman C, Larsson E, Klareskog L. Corticosteroids: from an idea to clinical use [review]. Best Pract Res Clin Rheumatol 2004;18:7-19.
21. Parente L, Solito E. Annexin 1: more than an anti-phospholipase protein [review]. Inflamm Res 2004;53:125-32.
22. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1β, phorbol ester, and corticosteroids. J Clin Invest 1994;93:1095-101.
23. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
24. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
25. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC. Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis. Arthritis Rheum 2000;43:2391-6.
26. Taylor PC, Peters AM, Paleolog E, 'Chapman PT, Elliott MJ, McCloskey R, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:38-47.
27. Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy. Br J Rheumatol 1997;36:643-50.
28. Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L. et al. Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 2002;41:484-9.
29. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
30. Van der Heijde DM, van't Hof MA, van Kiel PL, Theunisse LM, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
31. Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:654-61.
32. Punzi L, Schiavon F, Cavasin F, Ramonda R, Gambari PF, Todesco S. The influence of intra-articular hyaluronic acid on PGE2 and cAMP of synovial fluid. Clin Exp Rheumatol 1989;7:247-50.
33. Hishinuma T, Nakamura H, Sawai T, Uzuki M, Itabash Y, Mizugaki M. Microdetermination of prostaglandin E2 in joint fluid in rheumatoid arthritis patients using gas chromatography/selected ion monitoring. Prostaglandins Other Lipid Mediat 1999;58:179-86.
34. Bonder CS, Davies KV, Liu X, Hertzog PJ, Woodcock JM, Finlay-Jones JJ, et al. Endogenous interferon-α production by differentiating human monocytes regulates expression and function of the IL-2/IL-4 receptor γ chain. Cytokine 2002;17:187-96.
35. Kojima F, Naraba H, Miyamoto S, Beppu M, Aoki H, Kawai S. Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis. Arthritis Res Ther 2004;6:R355-65.
36. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
37. Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, Fritz P. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 1998;41:122-9.
38. Ek M, Engblom D, Saha S, Blomqvist A, Jakobsson PJ, Ericsson-Dahlstrand A. Inflammatory response: pathway across the blood-brain barrier. Nature 2001;410:430-1.
39. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001;167:2831-8.
40. Szczepanski A, Moatter T, Carley WW, Gerritsen ME. Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1: inhibition by glucocorticoids. Arthritis Rheum 1994;37:495-503.
41. Bryant CE, Appleton I, Mitchell JA. Vascular endothelial growth factor upregulates constitutive cyclooxygenase 1 in primary bovine and human endothelial cells. Life Sci 1998;62:2195-201.
42. Murphy JF, Fitzgerald DJ. Vascular endothelial growth factor induces cyclooxygenase-dependent proliferation of endothelial cells via the VEGF-2 receptor. FASEB J 2001;15:1667-9.
43. Onodera M, Horiuchi Y, Nakahama K, Muneta T, Mano Y, Morita I. Induction of cyclooxygenase-1 in cultured synovial cells isolated from rheumatoid arthritis patients. Inflamm Res 2004;53:217-22.
44. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
45. Nagashima M, Yoshino S, Aono H, Takai M, Sasano M. Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin Exp Immunol 1999;116:360-5.
46. Zwerina J, Haver S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277-90.